Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.41 |
| ▸ | AKT2 | P31751 | 20/20 | 0.41 |
| ▸ | AKT3 | Q9Y243 | 20/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24908886 | 1.00 | AKT1 (0.41) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL17771796 | 0.80 | AKT1 (0.37) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL17771782 | 0.80 | AKT1 (0.37) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL17771781 | 0.80 | AKT1 (0.37) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL17771686 | 0.80 | AKT1 (0.37) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL17771798 | 0.80 | AKT1 (0.37) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2738784 | 0.79 | AKT1 (0.39) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL12293083 | 0.79 | AKT1 (0.39) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL12288914 | 0.79 | AKT1 (0.39) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL24908888 | 0.79 | AKT1 (0.38) | AKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346805-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9328091-B2 | 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | GENENTECH, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150266852-A1 | 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150197496-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-07-16 | — | — | US | disclosed |
| EP-2404907-B1 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8895566-B2 | 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2173723-B3 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20140315887-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2014-10-23 | — | — | US | disclosed |
| US-8846683-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2250155-B1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20110251181-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| EP-2173723-B1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110160221-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2250155-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-2240483-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-2173723-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009089454-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089462-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009006569-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197496-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | AKT1 3/4885AKT2 4/4885AKT3 8/4885 |
| US-20140315887-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | AKT1 3/4885AKT2 4/4885AKT3 8/4885 |
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, PIK3CA | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
| US-20150266852-A1 | 5H-CYCLOPENTA[d]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT3, AKT2 | AKT1 7/4885AKT2 3/4885AKT3 2/4885 |
| US-20110160221-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | AKT1 3/4885AKT2 4/4885AKT3 8/4885 |
| US-20110251181-A1 | 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | AKT3, PIK3CA, AKT2 | AKT1 5/4885AKT2 3/4885AKT3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.